Rigel Pharmaceuticals | RIGL - Selling And Administration Expenses


Rigel Pharmaceuticals reported $27.04M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
Agenus USD 10.56M 13.04M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Celldex Therapeutics USD 7.84M 1.21M Dec/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Intrexon USD 10.31M 41K Jun/2024
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Veracyte USD 43.31M 8.43M Dec/2025